Form 4: Nuvalent CFO Sells Shares Under 10b5-1 Plan

Nuvalent's Chief Financial Officer, Alexandra Balcom, executed planned sales of Class A Common Stock totaling 27,588 shares in late September 2025, following the exercise of stock options.

Summary

• Alexandra Balcom, Nuvalent, Inc.'s Chief Financial Officer, reported transactions involving the company's Class A Common Stock.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024.
• On September 29, 2025, Balcom acquired 7,588 shares by exercising stock options at $6.89 per share and simultaneously sold these 7,588 shares at a weighted average price of $85.01 per share.
• On September 30, 2025, Balcom acquired an additional 20,000 shares by exercising stock options at $6.89 per share and subsequently sold these 20,000 shares at a weighted average price of $85.06 per share.
• Following these transactions, Balcom beneficially owns 61,734 shares of Class A Common Stock directly.
• The remaining stock options beneficially owned after these transactions total 59,638, with an exercise price of $6.89 and an expiration date of April 29, 2031.
• The options vest with 25% on April 29, 2022, and the remainder vesting monthly over three years, subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it reports insider selling, the transactions were pre-planned under a 10b5-1 plan, which mitigates negative interpretations. The significant difference between the exercise price and sale price highlights the stock's appreciation, which is positive for shareholders.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and orderly disposition of shares rather than a reaction to new, adverse information.
• The sale prices of $85.01 and $85.06 per share represent a significant gain over the exercise price of $6.89 per share, reflecting the company's stock appreciation.

Negatives

• The filing reports insider selling, which, while planned, can sometimes be perceived as a lack of conviction by management, though this is often for personal liquidity or diversification.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports past insider transactions.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's planned equity management.

Stakeholder Impact

• Shareholders: The transactions are routine and pre-planned, so they are unlikely to have a significant immediate impact. The high sale price relative to the exercise price could be seen as a positive indicator of past stock performance.

Key Dates

Recommendation

The filing details routine insider transactions (exercise of options and subsequent sale of shares) executed under a pre-arranged 10b5-1 trading plan. Such planned sales are generally not indicative of new fundamental information about the company's prospects. Therefore, this filing alone does not provide a basis for changing an investment thesis, leading to a 'hold' recommendation.

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Chief Financial Officer, Alexandra Balcom, Equity Sales